Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-01

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Inherited Retinal Diseases (IRDs) are a heterogeneous group of genetically based degenerative retinal disorders, representing a major cause of visual impairment and blindness in working-age adults. Despite the approval of the first gene therapy for RPE65-related IRD (voretigene neparvovec) in 2017, most IRDs remain untreatable, though many gene therapies are in development. Effective trial design and therapy development require a deep understanding of disease natural history and genotype-phenotype correlations. Over 270 IRD-associated genes are known (e.g., ABCA4, USH2A, RPGR, PRPH2, BEST1), each linked to distinct phenotypes and clinical progression. This retrospective study analyzes clinical, functional, and imaging data (Optical Coherence Tomography, Fundus Autofluorescence, Microperimetry) from a large, genetically characterized IRD cohort at the IRCCS Ospedale San Raffaele up to December 31, 2025. The aims are to describe natural history, define genotype-phenotype relationships, and identify structural and functional outcome measures useful for future clinical trial endpoints, supporting personalized prognosis and trial design.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT

NCT02575430

Leber Congenital Amaurosis (LCA) Retinitis Pigmentosa (RP)

COMPLETED

Natural History, Pathogenesis, and Outcome of Ocular Disorders

NCT02821767

Eye Disease

RECRUITING

Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases

NCT02309866

Retinitis Pigmentosa

UNKNOWN

Rod and Cone Mediated Function in Retinal Disease

NCT02617966

Retinal Degeneration Retinitis Pigmentosa Stargardt's Disease

RECRUITING

Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa

NCT00065455

Retinitis Pigmentosa

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinal Degenerations Retinitis Pigmentosa (RP) Stargardt Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No Intervention: Observational Cohort

no intervention, natural history study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participant completed at least one ophthalmological and retinal imaging examination at our center.
2. Clinically diagnosed with IRD, as per familiy history, clinical signs or symptoms, retinal imaging findings.
3. Definitive genetic diagnosis of IRD with adequate molecular test

Exclusion Criteria

1. Affected by other retinal or optic nerve conditions potentially affecting analyses (diabetic retinopathy, glaucoma).
2. History of retinotoxic medications (i.e., hydroxychloroquine, pentosan polysulfate sodium, tamoxifen, ritonavir, didanosine, MEK inhibitors) intake.
3. Unclear genetic diagnosis.
4. Incomplete or inadequate ophthalmological and imaging tests.

Eligible Sex

ALL

Accepts Healthy Volunteers

No